Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings Results

Corvus Pharmaceuticals (NASDAQ:CRVS) posted its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06), Zacks reports.

Corvus Pharmaceuticals Price Performance

Corvus Pharmaceuticals stock opened at $3.35 on Thursday. Corvus Pharmaceuticals has a one year low of $1.30 and a one year high of $10.00. The business’s fifty day moving average is $4.67 and its 200 day moving average is $6.08. The stock has a market capitalization of $215.26 million, a PE ratio of -3.60 and a beta of 0.91.

Analyst Upgrades and Downgrades

Several research firms recently commented on CRVS. Oppenheimer reissued an “outperform” rating and set a $15.00 price objective (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Corvus Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $12.63.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.